 |
Latest News |
| 6th September 2011 |
| |
Interim Results of CP024 Nasal hGH Phase 1 Program Show Comparable Bioactivity to Injection
|
|
| 5th April 2011 |
| |
PolyTherics and Critical Pharmaceuticals enter drug development collaboration with TSB funding
|
|
| 8th March 2011 |
| |
CriticalSorb Delivery Technology Shows Excellent Local Tolerability in Long Term Preclinical Studies
|
|
|
Technology |
| |
Critical Pharmaceuticals has developed two unique drug delivery technologies:
CriticalSorb for the non-invasive nasal delivery delivery of high-value biologic products and challenging small molecule drugs.
CriticalMix for the manufacture of highly active sustained release depot products for bimonthly, monthly or even less frequent injection.
|
| |
 |
| |
|
|
 |
| Event |
Date / Location |
Attendee |
|
Drug Delivery Partnerships
|
25-27 Jan, 2012 Las Vegas, NV
|
Dr Andy Lewis, Director Operations
www.iirusa.com/ddp
|
|
UK - India Innovation and Leadership Meeting
|
5-6 March, 2012 Bangalore, India
|
Dr Gareth King, CEO
www.biopharm2020.org
|
| BIO-Europe |
19-21 March, 2012 Amsterdam, The Netherlands |
Dr Gareth King, CEO
www.ebdgroup.com
|
|
SMi Controlled Release
|
28-29 March, 2012 London, UK
|
Dr Andy Lewis, Director Operations
www.smi-online.co.uk
|
|
BioTrinity
|
25-26 April, 2012 Newbury, UK
|
Dr Gareth King, CEO
www.biotrinity.com
|
|
EPIC Biotech
|
31 May, 2012 London, UK
|
Dr Gareth King, CEO
www.epicbiotech.com
|
|
BIO International Convention
|
18-21 June, 2012 Boston, MA
|
Dr Gareth King, CEO
convention.bio.org
|
|
ENDO 2012
|
23-26 June, 2012 Houston, TX
|
Dr Andy Lewis, Director Operations
www.endo-society.org
|
|
|
|
